Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-20

FDA Approved: COXANTO — Original Application (SOLA Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved COXANTO (oxaprozin) from SOLA Pharmaceuticals in its original application, enabling its use for pain and inflammation associated with rheumatoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COXANTO (OXAPROZIN)

Snippet

ORIG AP for COXANTO (OXAPROZIN)